• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Axonyx Announces Availability of Presentations on Phenserine From 7th International Conference on Alzheimer's and Parkinson's Disease on Corporate Website

Posted on: Monday, 21 March 2005, 15:00 CST

Includes Data Slides on (beta)-Amyloid Peptide Levels and Efficacy, Safety, Tolerability, and Pharmacokinetics of Phenserine in Mild-To-Moderate Alzheimer's Disease

Axonyx Inc. (NASDAQ: AXYX) today announced that three presentations from the 7th International Conference On Alzheimer's And Parkinson's disease held in Sorrento, Italy on Saturday, March 12, 2005 are currently available on the Axonyx corporate Website, www.axonyx.com in slide format.

The three data sets include: The Measurement of (beta)-Amyloid Peptide in Patients with Alzheimer's Disease as presented by Agneta Nordberg, M.D., Ph.D., Karolinska Institutet, Sweden; The Efficacy of Phenserine in the Treatment of Mild-to-Moderate Alzheimer's Disease as presented by Bengt Winblad M.D., Ph.D., Karolinska Institutet; and The Safety, Tolerability, and Pharmacokinetics of Phenserine in the Treatment of Alzheimer's Disease as presented by Ezio Giacobini M.D., Ph.D., Geneva University Hospital, Switzerland.

"We are privileged to have the ongoing opportunity to work closely with these and other eminent researchers," stated Gosse B. Bruinsma, M.D., President and Chief Executive Officer of Axonyx. "We highly value their experience in the field and look forward to future collaboration to maximize our potential for progress in treating Alzheimer's disease."

The PowerPoint presentations will be available on the Company's Website for the next 3 months.

About Axonyx

Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds for the treatment of Central Nervous System disorders.

Axonyx does not and cannot vouch for the accuracy of any information contained in the presentations referred to above that is not based upon data relating to Phenserine or to Axonyx's own clinical trials. This press release may contain forward-looking statements or predictions. These statements represent our judgment to date, and are subject to risks and uncertainties that could materially affect the Company including those risks and uncertainties described in the documents Axonyx files from time to time with the SEC, specifically Axonyx's annual report on Form 10-K. Axonyx cannot assure that the Phase IIb and/or other Phase III clinical trials, amendments thereto or others, if any, with Phenserine will prove successful, that the safety and efficacy profile of Phenserine exhibited in the previous small Phase II and Phase III trials will remain the same, be better or worse in future clinical trials, if any, that the preclinical results related to the regulation of beta-APP will be substantiated by the Phenserine Phase IIb clinical trial and that Phenserine will be able to slow the progression of Alzheimer's disease, that the Phase IIb clinical trial data will differentiate Phenserine from the currently marketed drugs, that any efficacy and safety results of a Phase III trial program, if pursued, will prove pivotal, that Axonyx will obtain the necessary financing to complete the Phenserine or other development programs, that the Company's development work on Phenserine will support an NDA filing, that the results of Phase III trials will allow Phenserine to be approved by the FDA, that the FDA will grant marketing approval for Phenserine, that if Phenserine is approved by the FDA, it will prove competitive in the market, and that Axonyx will obtain licensing or corporate partnership agreements that will enable successful development of or acceleration of the development of and optimize marketing opportunities for, Phenserine. Axonyx cannot assure that it will be able to advance any of its other potential memory enhancing compounds toward IND status or beyond. Axonyx undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Source: Business Wire

More News in this Category